Your Visitor’s No.
Tag Archive
Hepatitis A Vaccine
A team of researchers from upstate New York reported that a single dose of a formalin inactivated hepatitis A vaccine (Vaqta, Merck Sharp & Dohme) is well tolerated and highly protective against the disease. Investigators from the Kiryas Joel Institute of Medicine studied 1,037 uninfected children aged 2 to 16 in a Hasidic community that... »
Duchenne Muscular Dystrophy
A Memphis, Tenn., researcher who claims to have developed the first effective treatment for Duchenne muscular dystrophy received a U.S. patent for his technique, while the Food and Drug Administration began an investigation into whether he is following proper medical standards in his research. The investigator, who is chairman of the Cell Therapy Research... »
Acellular Pertussis Vaccine
Lederle Laboratories began shipping 10-dose vials of acellular pertussis vaccine (AceI-Imune) for use as part of children’s fourth and fifth DTP booster shots. Approved by the Food and Drug Administration last month, the vaccine consisting of cell free filtrates of B. pertussis, has a much lower incidence of side effects than the whole-cell vaccine.... »
Antibiotic Temafloxacin (Omniflox)
Abbott Laboratories re called the antibiotic temafloxacin (Omniflox) after the drug was linked to three deaths and 47 cases of severe adverse reactions, including hypoglycemia, liver and kidney dysfunction and hemolytic anemia and other blood cell abnormalities. The drug was approved in January by the Food and Drug Administration, and, like other fluoroquinolones, was... »
Lyme Disease
Researchers at the Gundersen Medical Foundation in La Crosse, Wise, announced that they had developed the first definitive test for Lyme disease. The laboratory kit detects a borreliacidal antibody active in the body seven days after exposure. An advisory committee to the Food and Drug Administration concluded that the widely used sleeping pill triazolam (Halcion,... »